Please login to the form below

Not currently logged in
Email:
Password:

ABT-493

This page shows the latest ABT-493 news and features for those working in and with pharma, biotech and healthcare.

AbbVie hepatitis C combo shows high cure rates

AbbVie hepatitis C combo shows high cure rates

The new phase II data on NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 - which recently started pivotal trials - showed that 97-98% of patients with genotype ... AbbVie is hoping to be able to show that ABT-493/ABT-530 can achieve high

Latest news

  • AbbVie takes 'one-size-fits-all' HCV regimen into phase III AbbVie takes 'one-size-fits-all' HCV regimen into phase III

    The co-formulated drug - which combines NS3/4A protease inhibitor ABT-493 with NS5A inhibitor ABT-530 - will be tested in six phase III trials involving patients with HCV genotypes

  • Hepatitis C therapies: dawn of a new age Hepatitis C therapies: dawn of a new age

    AbbVie is developing a DAA-based, IFN-free regimen centred on the protease inhibitor ABT 450. ... AbbVie is co-formulating its next-generation compounds ABT 530 and ABT 493, its ritonavir-free protease inhibitor, and Gilead has GS 5816 poised for phase 3

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....

Infographics